Emerging association between androgen deprivation therapy and male meningioma: Significant expression of luteinizing hormone-releasing hormone receptor in male meningioma

Q. Li, H. Coulson, Z. Klaassen, S. Sharma, P. Ramalingam, K. A. Moses, M. K. Terris

Research output: Contribution to journalArticle

6 Scopus citations


Background:There is emerging data suggesting a potential risk for meningioma growth stimulation in patients on luteinizing hormone-releasing hormone (LHRH) analogs for prostate cancer. We examined the expression of LHRH receptor (LHRH-R), progesterone receptor (PR) and Ki67 labeling index (LI) in specimens from male meningioma (MM) and female meningioma (FM) patients.Methods:A total of 24 MM and 24 FM paraffin blocks were retrieved from our institution between 1991 and 2008. Sections from the paraffin blocks were stained with mouse monoclonal antibodies against LHRH-R, PR and Ki67. All male patients had no previous history of prostate cancer (PCa) or previous history of hormone therapy.Results:LHRH-R positivity was extensive in 92% of MM and 88% of FM samples, with both showing strong intensity (67% and 79%, respectively). PR was positive in 20 of 24 (83%) MM and 23 of 24 (96%) FM samples. MM is less likely to exhibit Ki67 LI >4% compared with FM.Conclusions:The majority of MM and FM samples were strongly positive for LHRH-R expression and PR expression. The emerging association of androgen deprivation therapy and meningioma growth should be recognized in urological practice. Caution should be taken when considering LHRH agonist administration for patients with PCa and concurrent meningioma or previous history of meningioma.

Original languageEnglish (US)
Pages (from-to)387-390
Number of pages4
JournalProstate Cancer and Prostatic Diseases
Issue number4
Publication statusPublished - Dec 1 2013



  • Androgen deprivation therapy
  • Luteinizing hormone-releasing hormone receptor
  • Meningioma

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this